局部拉坦前列素对幼年豚鼠眼压及近视进展的影响
在形觉剥夺幼年豚鼠模型中,每日局部滴用0.005%拉坦前列素(n=10)较人工泪液对照(n=10)显著降低眼压并减缓近视进展;第10周时拉坦前列素组眼间眼压差为-5.17±0.96 mmHg(P<0.001),眼间等效屈光度差为-2.25±0.54 D(P=0.03),而对照组分别为1.80±1.16 mmHg(P=0.525)和-8.2±0.71 D(P<0.001)。
要点
- 形觉剥夺幼年豚鼠中,拉坦前列素组第10周眼间眼压差-5.17±0.96 mmHg(P<0.001),显著降低眼压。
- 拉坦前列素组第10周眼间等效屈光度差-2.25±0.54 D(P=0.03),近视进展较对照组的-8.2±0.71 D(P<0.001)减缓。
- 拉坦前列素组第10周眼间光学轴长差0.06±0.02 mm(P=0.202),对照组为0.29±0.04 mm(P<0.001)。
核心结论
- 在形觉剥夺豚鼠模型中,拉坦前列素显著减少近视的发展;虽需进一步研究其潜在机制,但结果开启了近视控制新疗法方向的可能性。
研究设计与样本
- 两周龄色素豚鼠行单眼形觉剥夺,形觉剥夺开始1周后每日局部滴用0.005%拉坦前列素(n=10)或人工泪液(对照,n=10),全部治疗再持续9周。
- 使用眼压计、检影验光和高频A超分别监测眼压、屈光不正和眼轴尺寸。
主要发现
- 基线及第10周平均眼间眼压差(±SEM):对照组-0.30±0.51与1.80±1.16 mmHg(P=0.525),拉坦前列素组0.07±0.35与-5.17±0.96 mmHg(P<0.001)。
- 基线及第10周眼间光学轴长差:对照组0.00±0.015与0.29±0.04 mm(P<0.001),拉坦前列素组0.02±0.02与0.06±0.02 mm(P=0.202)。
- 基线及第10周眼间屈光不正差:对照组+0.025±0.36与-8.2±0.71 D(P<0.001),拉坦前列素组-0.15±0.35与-2.25±0.54 D(P=0.03)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文结论指出,尚需进一步研究其潜在机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine whether latanoprost, a prostaglandin analog proven to be very effective in reducing intraocular pressure (IOP) in humans, can also slow myopia progression in the guinea pig form deprivation (FD) model. METHODS: Two-week-old pigmented guinea pigs underwent monocular FD and daily topical latanoprost (0.005%, n = 10) or artificial tears (control, n = 10) starting 1 week after the initiation of FD, with all treatments continuing for a further 9 weeks. Tonometry, retinoscopy, and high-frequency A-scan ultrasonography were used to monitor IOP, refractive error, and ocular axial dimensions, respectively. RESULTS: Latanoprost significantly reduced IOP and slowed myopia progression. Mean interocular IOP differences (±SEM) recorded at baseline and week 10 were -0.30 ± 0.51 and 1.80 ± 1.16 mm Hg (P = 0.525) for the control group and 0.07 ± 0.35 and -5.17 ± 0.96 mm Hg (P < 0.001) for the latanoprost group. Equivalent interocular differences for optical axial length at baseline and week 10 were 0.00 ± 0.015 and 0.29 ± 0.04 mm (P < 0.001; control) and 0.02 ± 0.02 and 0.06 ± 0.02 mm (P = 0.202; latanoprost), and for refractive error were +0.025 ± 0.36 and -8.2 ± 0.71 diopter (D) (P < 0.001; control), and -0.15 ± 0.35 and -2.25 ± 0.54 D (P = 0.03; latanoprost). CONCLUSIONS: In the FD guinea pig model, latanoprost significantly reduces the development of myopia. Although further investigations into underlying mechanisms are needed, the results open the exciting possibility of a new line of myopia control therapy.
引用
- El-Nimri NW, Wildsoet CF. Effects of Topical Latanoprost on Intraocular Pressure and Myopia Progression in Young Guinea Pigs. Invest Ophthalmol Vis Sci. 2018. PMID: 29847673. doi:10.1167/iovs.17-22890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。